Preclinical models for pulmonary drug delivery

Expert Opinion on Drug Delivery

Volumn 6, Issue 11, 2009, Pages 1231-1245

  Fernandes, Cláudia A ^a   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

cell cultures; inhalation; intratracheal instillation; isolated perfused lung; large mammals, pulmonary deposition; small rodents

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CALCITONIN; CORTICOSTEROID; ENALAPRIL; ENALAPRILAT; ERGOTAMINE; ERYTHROPOIETIN; FENTANYL; GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOSARTAN; METOPROLOL; MORPHINE; MUCOLYTIC AGENT; PARATHYROID HORMONE; PROPRANOLOL; PROTEIN DERIVATIVE; RECOMBINANT HUMAN INSULIN; TALINOLOL; TECHNETIUM 99M; TERBUTALINE; VACCINE;

AEROSOL; AIRWAY; AREA UNDER THE CURVE; ASTHMA; BLOOD GLUCOSE MONITORING; BRONCHIOLE; BRONCHUS MUCOSA; CELL CULTURE; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLARA CELL; CLINICAL EVALUATION; COLUMNAR EPITHELIUM; CULTURE TECHNIQUE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG MARKETING; DRUG METABOLISM; DRUG PENETRATION; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSPORT; DRY POWDER; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; EPITHELIUM CELL; EX VIVO STUDY; EXPERIMENTAL DOG; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MODEL; EXPERIMENTAL MONKEY; EXPERIMENTAL MOUSE; EXPERIMENTAL PIG; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; FOOD AND DRUG ADMINISTRATION; GAMMA SCINTIGRAPHY; GENE THERAPY; GOBLET CELL; HUMAN; HUMIDITY; HYDROPHILICITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INHALATION; INNATE IMMUNITY; INSPIRATORY CAPACITY; INSULIN DEPENDENT DIABETES MELLITUS; ISOLATED LUNG; LIVER METABOLISM; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG ALVEOLUS WALL; LUNG CANCER; LUNG EXTRAVASCULAR FLUID; LUNG GAS EXCHANGE; LUNG INFECTION; LUNG LAVAGE; LUNG PARENCHYMA; LUNG PERFUSION; LUNG RESECTION; LUNG VOLUME; LUNG WEIGHT; MAXIMUM PLASMA CONCENTRATION; MEASLES; MIGRAINE; MONOLAYER CULTURE; MUCOCILIARY CLEARANCE; MUCOUS CELL; NAUSEA; NEBULIZATION; NEGATIVE PRESSURE VENTILATION; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE; PAIN; PARTICLE SIZE; PATHOGENESIS; PINOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY TUMOR; PULMONARY HYPERTENSION; RESEARCH ETHICS; RESPIRATORY SYSTEM; REVIEW; RNA INTERFERENCE; ROOM TEMPERATURE; SHEEP; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY; TRACHEA; TUBERCULOSIS; TURBINATE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT; VASCULARIZATION; ANIMAL; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; METHODOLOGY;

ADMINISTRATION, INHALATION; ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG;

EID: 75349108981     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425240903241788     Document Type: Review

References (136)

1. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care 2005;50(9):1139-50
2. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008;21(1):61-70
3. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50(9):1161-76
4. Durcan N, Murphy C, Cryan SA. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 2008;5(4):559-66
5. Minne A, Huaux F, Jaworska J, et al. Safety evaluation of pulmonary influenza vaccination in healthy and 'asthmatic' mice. Vaccine 2008;26(19):2360-8
6. Bivas-Benita M, Ottenhoff TH, Junginger HE, et al. Pulmonary DNA vaccination: concepts, possibilities and perspectives. J Control Release 2005;107(1):1-29
7. Minne A, Louahed J, Mehauden S, et al. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 2007;122(3):316-25
8. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6(1):67-74
9. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006;68:403-29
10. Silin DS, Lyubomska OV, Jirathitikal V, et al. Oral vaccination: where we are? Expert Opin Drug Deliv 2007;4(4):323-40
11. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006;58(9-10):1076-88
12. Armer TA, Shrewsbury SB, Newman SP, et al. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 2007;23(12):3177-87
13. Kling J. Inhaled insulin's last gasp? Nat Biotechnol 2008;26(5):479-80
14. Bosquillon C, Preat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 2004;96(2):233-44
15. Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci 2004;93(5):1241-52
16. Dumont JA, Bitonti AJ, Clark D, et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005;18(3):294-303
17. McWilliam AS, Holt PG. Immunobiology of dendritic cells in the respiratory tract: steady-state and inflammatory sentinels? Toxicol Lett 1998;102-103:323-9
18. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):588-99
19. Hickey AJ. Inhalation aerosols - Physical and biological basis for therapy, Marcel Dekker, New York, 1996
20. Houtmeyers E, Gosselink R, Gayan-Ramirez G, et al. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999;13(5):1177-88
21. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007;52(9):1134-46
22. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61(2):158-71
23. Chilvers MA, O'Callaghan C. Local mucociliary defence mechanisms. Paediatr Respir Rev 2000;1(1):27-34
24. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19(1):3-36
25. Perez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008;1778(7-8):1676-95
26. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5(1):58-68
27. Patton JS, McCabe JG, Hansen SE, et al. Absorption of human growth hormone from the rat lung. Biotechnol Ther 1990;1(3):213-28
28. Nag K, Hillier A, Parsons K, et al. Interactions of serum with lung surfactant extract in the bronchiolar and alveolar airway models. Respir Physiol Neurobiol 2007;157(2-3):411-24
29. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br Med Bull 2002;61:45-61
30. Lombry C, Edwards DA, Preat V, et al. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004;286(5):L1002-8
31. Ducreux J, Vanbever R. Crucial biopharmaceutical issues facing macromolecular candidates for inhalation: the role of macrophages in pulmonary protein clearance. Respir Drug Deliv Eur 2007; 1:31-41
32. Ross HH, Romrell LJ, Kaye GI. Respiratory system, Histology - A text and atlas; Williams & Wilkins, Baltimore1995. p. 530-57
33. Kim CS, Folinsbee LJ. Physiological and biomechanical factors relevant to inhaled drug delivery, Inhalation delivery of therapeutic peptides and protein; M. Dekker, New York1997. p. 3-22
34. Elbert KJ, Schafer UF, Schafers HJ, et al. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm Res 1999;16(5):601-8
35. Matsukawa Y, Lee VH, Crandall ED, et al. Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J Pharm Sci 1997;86(3):305-9
36. Préparations pour inhalation: évaluation aérodynamique des particules fines-Dose des particules fines et distribution granulométrique des particules, European Pharmacopoeia, Addendum, Strasbourg, 2002, pp. 225-237
37. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008;21(1):77-84
38. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000;208(1-2):49-60
39. Phalen RF, Oldham MJ, Wolff RK. The relevance of animal models for aerosol studies. J Aerosol Med Pulm Drug Deliv 2008;21(1):113-24
40. Steimer A, Franke H, Haltner-Ukomado E, et al. Monolayers of porcine alveolar epithelial cells in primary culture as an in vitro model for drug absorption studies. Eur J Pharm Biopharm 2007;66(3):372-82
41. Grainger CI, Greenwell LL, Martin GP, et al. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm 2008;71(2):318-324
42. Manford F, Tronde A, Jeppsson AB, et al. Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sci 2005;26(5):414-20
43. Tronde A, Norden B, Marchner H et al. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 2003;92(6):1216-1233
44. Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 2008;128(3):224-32
45. Lin H, Li H, Cho HJ, et al. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 2007;96(2):341-50
46. Blank F, Rothen-Rutishauser BM, Schurch S, et al. An optimized in vitro model of the respiratory tract wall to study particle cell interactions. J Aerosol Med 2006;19(3):392-405
47. Geys J, Coenegrachts L, Vercammen J, et al. In vitro study of the pulmonary translocation of nanoparticles: a preliminary study. Toxicol Lett 2006;160(3):218-26
48. Fiegel J, Ehrhardt C, Schaefer UF, et al. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res 2003;20(5):788-96
49. Madlova M, Bosquillon C, Asker D, et al. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Pharmacol 2009;61(3):293-301
50. Ehrhardt C, Kneuer C, Fiegel J, et al. Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. Cell Tissue Res 2002;308(3):391-400
51. Fuchs S, Hollins AJ, Laue M, et al. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res 2003;311(1):31-45
52. Saha P, Kim K, Yamahara H, et al. Influence of lipophilicity on β-blocker permeation across rat alveolar epithelial cell monolayers. J Control Release 1994;32:191-200
53. Matsukawa Y, Yamahara H, Lee VH, et al. Horseradish peroxidase transport across rat alveolar epithelial cell monolayers. Pharm Res 1996;13(9):1331-5
54. Matsukawa Y, Yamahara H, Yamashita F, et al. Rates of protein transport across rat alveolar epithelial cell monolayers. J Drug Target 2000;7(5):335-42
55. Kim KJ, Fandy TE, Lee VH, et al. Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 2004;287(3):L616-22
56. Dodoo AN, Bansal SS, Barlow DJ, et al. Use of alveolar cell monolayers of varying electrical resistance to measure pulmonary peptide transport. J Pharm Sci 2000;89(2):223-31
57. Rogers CS, Abraham WM, Brogden KA, et al. The porcine lung as a potential model for cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;295(2):L240-63
58. Steimer A, Laue M, Franke H, et al. Porcine alveolar epithelial cells in primary culture: morphological, bioelectrical and immunocytochemical characterization. Pharm Res 2006;23(9):2078-93
59. Grainger CI, Greenwell LL, Lockley DJ, et al. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res 2006;23(7):1482-90
60. Mathias NR, Timoszyk J, Stetsko PI, et al. Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target 2002;10(1):31-40
61. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9-10):1030-60
62. Widera A, Kim KJ, Crandall ED, et al. Transcytosis of GCSF-transferrin across rat alveolar epithelial cell monolayers. Pharm Res 2003;20(8):1231-8
63. Kim KJ, Matsukawa Y, Yamahara H, et al. Absorption of intact albumin across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 2003;284(3):L458-65
64. Sivadas N, O'Rourke D, Tobin A, et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm 2008;358(1-2):159-67
65. Matilainen L, Toropainen T, Vihola H, et al. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Control Release 2008;126(1):10-6
66. Blank F, Rothen-Rutishauser B, Gehr P. Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am J Respir Cell Mol Biol 2007;36(6):669-77
67. Sakagami M, Byron PR, Venitz J, et al. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. J Pharm Sci 2002;91(2):594-604
68. Niven RW, Byron PR. Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract. Pharm Res 1988;5(9):574-9
69. Tronde A, Krondahl E, von Euler-Chelpin H, et al. High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. Peptides 2002;23(3):469-78
70. Niemeier RW. The isolated perfused lung. Environ Health Perspect 1984;56:35-41
71. Uhlig S, Heiny O. Measuring the weight of the isolated perfused rat lung during negative pressure ventilation. J Pharmacol Toxicol Methods 1995;33(3):147-52
72. Valle MJ, Gonzalez LF, Sanchez NA. Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulm Pharmacol Ther 2008;21(2):298-303
73. Saumon G, Soler P, Martet G. Effect of polycations on barrier and transport properties of alveolar epithelium in situ. Am J Physiol 1995;269(2 Pt 1):L185-94
74. Ewing P, Eirefelt SJ, Andersson P, et al. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. J Aerosol Med Pulm Drug Deliv 2008;21(2):169-80
75. Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. Eur J Pharm Sci 2005;25(4-5):369-78
76. Tronde A, Norden B, Jeppsson AB, et al. Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability. J Drug Target 2003;11(1):61-74
77. Koshkina NV, Waldrep JC, Roberts LE, et al. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7(10):3258-62
78. Myrdal PB, Karlage K, Kuehl PJ, et al. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. Carcinogenesis 2007;28(5):957-61
79. Tam JM, McConville JT, Williams RO, et al. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 2008;97(11):4915-33
80. Sinswat P, Overhoff KA, McConville JT, et al. Nebulization of nanoparticulate amorphous or crystalline tacrolimus-single-dose pharmacokinetics study in mice. Eur J Pharm Biopharm 2008;69(3):1057-66
81. Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 2007;32(2):140-50
82. Onischuk AA, Tolstikova TG, Sorokina IV, et al. Analgesic effect from ibuprofen nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv 2009; [Epub ahead of print]
83. Onischuk AA, Tolstikova TG, Sorokina IV, et al. Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv 2008;21(3):231-43
84. Manford F, Riffo-Vasquez Y, Spina D, et al. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice. J Pharm Pharmacol 2008;60(10):1305-10
85. Choi WS, Murthy GG, Edwards DA, et al. Inhalation delivery of proteins from ethanol suspensions. Proc Natl Acad Sci USA 2001;98(20):11103-7
86. Bartus RT, Emerich D, Snodgrass-Belt P, et al. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2004;310(2):828-35
87. Jalalipour M, Najafabadi AR, Gilani K, et al. Effect of dimethyl-beta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. J Pharm Sci 2008;97(12):5176-85
88. Ricciardolo FL, Nijkamp F, De R, et al. The guinea pig as an animal model for asthma. Curr Drug Targets 2008;9(6):452-65
89. Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med 2008;58(4):324-40
90. Garcia-Contreras L, Fiegel J, Telko MJ, et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 2007;51(8):2830-6
91. Jansen M, Darby I, Abribat T, et al. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm 2004;276(1-2):75-81
92. Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 2006;95(11):2438-51
93. Vick A, Wolff R, Koester A, et al. A 6-month inhalation study to characterize the toxicity, pharmacokinetics, and pharmacodynamics of human insulin inhalation powder (HIIP) in beagle dogs. J Aerosol Med 2007;20(2):112-26
94. Bjertnaes LJ, McGuire R, Jodoin J, et al. Nebulized nitric oxide/nucleophile adduct reduces pulmonary vascular resistance in mechanically ventilated septicemic sheep. Crit Care Med 2005;33(3):616-22
95. Sandifer BL, Brigham KL, Lawrence EC, et al. Effects of aerosol vs IV UT-15 on prostaglandin H2 analog-induced pulmonary hypertension in sheep. Chest 2005;128(Suppl 6):616S
96. Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 2006;34(3):252-69
97. Hofmann W, Asgharian B. The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol Sci 2003;73(2):448-56
98. Stone KC, Mercer RR, Gehr P, et al. Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 1992;6(2):235-43
99. Alvarez CA, Wiederhold NP, McConville JT, et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007;55(1):68-74
100. Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18(10):1405-10
101. Zijlstra GS, Brandsma CA, Harpe MF, et al. Dry powder inhalation of hemin to induce heme oxygenase expression in the lung. Eur J Pharm Biopharm 2007;67(3):667-75
102. Nadithe V, Rahamatalla M, Finlay WH, et al. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci 2003;92(5):1066-76
103. Martin AR, Thompson RB, Finlay WH. MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles. J Aerosol Med Pulm Drug Deliv 2008;21(4):335-42
104. Tseng CL, Wu SY, Wang WH, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008;29(20):3014-22
105. Gautam A, Densmore CL, Waldrep JC. Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther 2000;2(4):318-23
106. Rozlog LA, Kiecolt-Glaser JK, Marucha PT, et al. Stress and immunity: implications for viral disease and wound healing. J Periodontol 1999;70(7):786-92
107. Jacob ST, Ghoshal K, Sheridan JF. Induction of metallothionein by stress and its molecular mechanisms. Gene Expr 1999;7(4-6):301-10
108. Pauluhn J, Thiel A. A simple approach to validation of directed-flow nose-only inhalation chambers. J Appl Toxicol 2007;27(2):160-7
109. Verma RK, Kaur J, Kumar K, et al. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008;52(9):3195-201
110. Lombry C, Marteleur A, Arras M, et al. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res 2004;21(1):127-35
111. Deshpande DS, Blanchard JD, Schuster J, et al. Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J Aerosol Med 2005;18(1):34-44
112. Rich PB, Douillet CD, Hurd H, et al. Effect of ventilatory rate on airway cytokine levels and lung injury. J Surg Res 2003;113(1):139-45
113. Minne A, Jaworska J, Gerhold K, et al. Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyper-reactivity in mice. Clin Exp Allergy 2007;37(8):1250-8
114. Courrier HM, Pons F, Lessinger JM, et al. In vivo evaluation of a reverse water-in-fluorocarbon emulsion stabilized with a semifluorinated amphiphile as a drug delivery system through the pulmonary route. Int J Pharm 2004;282(1-2):131-40
115. Massaro D, Massaro GD, Clerch LB. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol 2004;287(5):L1066-70
116. Bolognin M, Kirschvink N, Leemans J, et al. Characterisation of the acute and reversible airway inflammation induced by cadmium chloride inhalation in healthy dogs and evaluation of the effects of salbutamol and prednisolone. Vet J 2009;179(3):443-50
117. Youn YS, Kwon MJ, Na DH, et al. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J Control Release 2008;125(1):68-75
118. Codrons V, Vanderbist F, Verbeeck RK, et al. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003;92(5):938-50
119. Newman S, Byron P, Dalby R et al, Respiratory drug delivery - Essential theory and practice, Richmond USA: RDD Online/Virginia Commonwealth University, 2009
120. Chatziioannou AF. Instrumentation for molecular imaging in preclinical research: micro-PET and micro-SPECT. Proc Am Thorac Soc 2005;2(6):533-11
121. Fok TF, Al-Essa M, Kirpalani H, et al. Estimation of pulmonary deposition of aerosol using gamma scintigraphy. J Aerosol Med 1999;12(1):9-15
122. Martorana PA, Cavarra E, Lucattelli M, et al. Models for COPD involving cigarette smoke. Drug Discov today: disease models 2006;3(3):225-30
123. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008;295(3):L379-99
124. Zosky GR, Sly PD. Animal models of asthma. Clin Exp Allergy 2007;37(7):973-88
125. Ehrhardt C, Collnot EM, Baldes C, et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res 2006;323(3):405-15
126. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv 1995;2(1):1-20
127. Derelanko MJ, Hollinger MA. Handbook of toxicology, CRC Press, Boca Raton 2002
128. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60(2):532-8
129. Bayat S, Menaouar A, Anglade D, et al. In vivo quantitation of epithelial lining fluid in dog lung. Am J Respir Crit Care Med 1998;158(6):1715-23
130. Ghofrani HA, Kohstall MG, Weissmann N, et al. Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. Am J Physiol Lung Cell Mol Physiol 2001;280(5):L896-904
131. Icard P, Saumon G. Alveolar sodium and liquid transport in mice. Am J Physiol 1999;277(6 Pt 1):L1232-8
132. Kimoto T, Takanashi M, Mukai H, et al. Effect of adrenergic stimulation on drug absorption via passive diffusion in Caco-2 cells. Int J Pharm 2009;368(1-2):31-6
133. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol 2005;32(4):281-9
134. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10(7):1093-5
135. Lai Y-L. Comparative ventilation of the normal lung. In: Parent RA, editors, Treatise on pulmonary toxicology - comparative biology of the normal lung; Parent RA editors, Boca Raton, FL. 1992. p. 217-39
136. Asgharian B, Kelly JT, Tewksbury EW. Respiratory deposition and inhalability of monodisperse aerosols in Long-Evans rats. Toxicol Sci 2003;71(1):104-11